AstraZeneca divests seven ‘mature’ brands to refocus its portfolio 01-Oct-2019 By Vassia Barba AstraZeneca enters a $270m deal with Cheplapharm to divest seven drugs, in order to reduce its portfolio of ‘mature’ medicines and reinvest in other therapeutic areas.